|
|
|
| home > white papers > Value-Added Processing and Quality By Design Principles Help Meet High-Quality Demands - West Pharmaceutical Services, Inc. |
|
|
 WHITE PAPERS |
|
West Pharmaceutical Services, Inc.
|
|
Value-Added Processing and Quality By Design Principles Help Meet High-Quality Demands
|
|
The current pharmaceutical market has faced a variety of challenges,
including increasing expectations for quality from end-users and
regulatory agencies driven by concern for patient safety. While
pharmaceutical companies are working to assure that new quality and
compliance paradigms are met, a balance must be achieved between the
reality of managing costs in an effort to provide a product that meets
the requirements of payers along with facilitating profitability in
order to continue adequate business reinvestment.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Sphere Fluidics introduces latest version of Cyto-Mine Studio Software Suite
Cambridge, UK, 27 August 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced an updated version of its Cyto-Mine® Studio Software Suite, a collection of software controlling operation of its Cyto-Mine Single Cell Analysis System, data acquisition and follow-up analysis. The latest software version includes new functionality to further enhance users’ workflows in biologics discovery and cell line development.
More info >> |
|
 |
White Papers |
 |
|
Pharmacovigilance and Risk Management Information in Centralised Applications in the EU
United BioSource Corporation (UBC)
Getting a new medication approved for the EU market through the centralised procedure can be complex and needs expertise. The new EU pharmacovigilance legislation (Good Vigilance Practice, GVP) is now in effect and applicants need to be fully compliant. It is critical to have a thorough understanding of the regulatory process and requirements, and the expectations with regards to the pharmacovigilance system and the risk management plan. Ensuring consistency and an appropriate level of detail in the documentation submitted as part of the approval process will help prevent unnecessary delays.
More info >> |
|
 |
Industry Events |
 |
ESMO Targeted Anticancer Therapies Congress 2020
2-4 March 2020, Paris, France
A unique and international mix of experts, researchers and decision
makers both from academia and industry across the globe, will convene
in Paris for a three-day Congress aiming at exchanging knowledge,
experience and research innovations in cancer.
TAT
2020 will focus, among others, on novel strategies in immuno-oncology,
personalised medicine and molecular tumour boards, preclinical studies
to identify effective combination therapies, use of microbiome, tumour
agnostic trials, ADC technology, oncolytics, multispecific biological
constructs and targeting cytokines.
Participating in TAT 2020 will offer you the possibility to take part in
interdisciplinary discussions inspiring new ideas and new
collaborations.
More info >> |
|
|
|
